Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07462507 · ClinicalTrials.gov registry record · Phase 2
Inflammation in Primary and Secondary Malignancies of the Central Nervous System Using [C-11]-CS1P1
A Phase 2 study, sponsored by Washington University School of Medicine.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 104
- Enrollment target
NCT07462507 is a Phase 2 study that is actively recruiting participants, run by Washington University School of Medicine. The registered enrollment target is 104 participants.
The verdict
NCT07462507, a Phase 2 study, is actively recruiting participants, sponsored by Washington University School of Medicine.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 104 participants
- Enrollment target
Study Summary
Adult patients with primary or secondary central nervous system malignancies will be invited to undergo a baseline \[C-11\]-CS1P1 PET scan and a follow-up scan within 24 months of the baseline scan (preferably within 6-months post-treatment).The study will describe patterns of tracer uptake in tumors and normal brain and explore how these patterns relate to MRI findings, treatments received, and clinical outcomes.
Interventions
- DRUG [C-11]-CS1P1
- DEVICE Brain MRI
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 104 participants |
| Start Date | 2026-04-16 |
| Est. Completion | 2033-06-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07462507
The ClinicalTrials.gov registry entry for NCT07462507 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 104 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which [C-11]-CS1P1 is the first listed.
NCT07462507 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07462507 about?
NCT07462507 is a clinical study titled "Inflammation in Primary and Secondary Malignancies of the Central Nervous System Using [C-11]-CS1P1". Adult patients with primary or secondary central nervous system malignancies will be invited to undergo a baseline \[C-11\]-CS1P1 PET scan and a follow-up scan within 24 months of the baseline scan (preferably within 6-months post-treatment).The study will describe patterns of tracer uptake in tumor...
What is the current status of trial NCT07462507?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 104 participants. The study started on 2026-04-16. Estimated completion is 2033-06-30.
What interventions are being tested in trial NCT07462507?
The interventions under investigation include: [C-11]-CS1P1 (DRUG), Brain MRI (DEVICE).
Who is sponsoring clinical trial NCT07462507?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.